SciNeuro is dedicated to developing medicines for neurological diseases. Our initial focus is neurodegenerative diseases in which structure and function of neurons are progressively damaged and lost. As a result, patients lose their natural ability to move, speak, remember, or think. Neurodegeneration can present in various forms, such as Parkinson’s disease (PD) and Alzheimer’s disease (AD), two common neurodegenerative diseases affecting patients worldwide, as well as rare conditions like amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA).
In recent years, the rapid progress of human genetic studies and the advent of genomic technologies have revealed molecular culprits (proteins) of neurodegeneration as promising therapeutic targets.